| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
52,373,000 |
| Market
Cap: |
2.52(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.85 - $52.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 474 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
134,738 |
259,234 |
263,234 |
303,833 |
| Total Sell Value |
$6,189,261 |
$10,761,080 |
$10,907,920 |
$12,010,179 |
| Total People Sold |
5 |
7 |
7 |
7 |
| Total Sell Transactions |
12 |
29 |
31 |
34 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mclaughlin Kevin F |
|
– • – |
2022-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
6,100 |
|
- |
|
| Gilman Steven C |
|
– • – |
2022-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
6,100 |
|
- |
|
| Rubino Alan L |
|
– • – |
2022-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
11,994 |
|
- |
|
| Zerbe Robert L Md |
|
– • – |
2022-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
4,350 |
|
- |
|
| Hagen Heidi |
|
– • – |
2022-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
12,850 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2022-03-01 |
4 |
AS |
$41.41 |
$693,431 |
D/D |
(16,738) |
49,176 |
|
-34% |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2022-03-01 |
4 |
OE |
$10.95 |
$289,500 |
D/D |
20,000 |
55,914 |
|
- |
|
| Flynn Sean C. |
VP, General Counsel |
• – – |
2022-02-19 |
4 |
D |
$34.90 |
$30,328 |
D/D |
(869) |
3,445 |
|
- |
|
| Flynn Sean C. |
VP, General Counsel |
• – – |
2022-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
4,314 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2022-02-19 |
4 |
D |
$34.90 |
$135,238 |
D/D |
(3,875) |
156,432 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2022-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,937 |
160,307 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2022-02-19 |
4 |
D |
$34.90 |
$25,477 |
D/D |
(730) |
45,914 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2022-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
46,644 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2022-02-19 |
4 |
D |
$34.90 |
$43,555 |
D/D |
(1,248) |
10,247 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2022-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,812 |
11,495 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2022-02-11 |
4 |
D |
$35.26 |
$114,630 |
D/D |
(3,251) |
151,370 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
154,621 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2022-02-11 |
4 |
D |
$35.26 |
$27,327 |
D/D |
(775) |
44,894 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,625 |
45,669 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2022-02-11 |
4 |
D |
$35.26 |
$55,147 |
D/D |
(1,564) |
8,683 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
10,247 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2022-02-06 |
4 |
D |
$33.91 |
$103,392 |
D/D |
(3,049) |
147,121 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2022-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,937 |
150,170 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2022-02-06 |
4 |
D |
$33.91 |
$31,570 |
D/D |
(931) |
6,747 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2022-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
7,678 |
|
- |
|
303 Records found
|
|
Page 6 of 13 |
|
|
0.55 (1.13%) 
